Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study
{{output}}
Aim: Sotrovimab is an engineered human monoclonal antibody that binds a conserved region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab for treatment of mild to moderate COVID-19 in nonhospitalized participants with ≥1 ris... ...
